Market Cap 4.05B
Revenue (ttm) 490.73M
Net Income (ttm) -25.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5.21%
Debt to Equity Ratio 0.00
Volume 1,763,900
Avg Vol 2,211,104
Day's Range N/A - N/A
Shares Out 92.99M
Stochastic %K 30%
Beta 1.13
Analysts Strong Sell
Price Target $53.21

Company Profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport di...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 969 7879
Website: travere.com
Address:
3611 Valley Centre Drive, Suite 300, San Diego, United States
Holdyn_Baggins
Holdyn_Baggins May. 12 at 6:16 PM
$TVTX come on bulls. Get off the damn short bus and join us on the short train.
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 11 at 5:30 PM
$TVTX trading this thing is like playing with a balloon. It just kind of floats around. Kind of fun. I flipped it long last time so don’t say I never did anything for you bulls.
0 · Reply
gookvook
gookvook May. 10 at 6:25 PM
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 7 at 4:08 PM
$TVTX so good… mmm mmm
0 · Reply
DeadInvestor
DeadInvestor May. 7 at 3:55 PM
$TVTX My math suggests $3.9 billion peak sales. IgAN at 990 PSFs per quarter is 1.5% of 70,000 population. Thats 6% per year. Assume this peaks at 1/3rd of population, who remain on Filspari in perpetuity, assuming a $90K net revenue (payer discount and royalties owed), that’s $2.1 billion in annual sales. Assuming FSGS can also get to 1/3rd of 30,000 population, at a $180K net revenue, that’s another $1.8 billion. $3.9 billion combined, without expanding TAM population (which TVTX intends to do). Fair valuation conservatively at 2x sales, that’s $7.8 billion market cap, or $81 / share.
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 7 at 3:53 PM
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 7 at 3:51 PM
$TVTX FREE MONEY!!!
0 · Reply
DeadInvestor
DeadInvestor May. 7 at 3:17 PM
$TVTX @Night_Owl_Biotech Will you update and share your biotech valuation tables, now with FSGS approval and expectation of $3.1 billion peak Filspari sales? Curious how under valued TVTX is now, as compared to similar biotechs.
3 · Reply
DeadInvestor
DeadInvestor May. 7 at 3:13 PM
$TVTX I believe $NVS is lead acquirer now, after failed endpoint not met on IgAN trial. They will still submit to FDA, but unlikely to approve. Therefore acquire TVTX at $75 / share.
0 · Reply
DeadInvestor
DeadInvestor May. 7 at 3:10 PM
$TVTX Convertible notes oversubscribed ($475M vs $400M offering) at a conversion price of $65 / share. This is constructed well, in that it will result in a substantial unwinding of the 15% of float short positions (Institutional holdings are currently 110% of shares outstanding). Very bullish setup. If it can push through the $55 resistance, smooth sailing to $70+ and eventual acquisition likely.
0 · Reply
Latest News on TVTX
Travere Therapeutics Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 8 days ago

Travere Therapeutics Earnings Call Transcript: Q1 2026


Travere Therapeutics reports Q1 EPS 5c, consensus (5c)

2026-05-04T20:06:42.000Z - 8 days ago

Travere Therapeutics reports Q1 EPS 5c, consensus (5c)


Travere Therapeutics rises 33.0%

2026-04-14T16:06:59.000Z - 4 weeks ago

Travere Therapeutics rises 33.0%


Travere Therapeutics rises 32.5%

2026-04-14T14:06:54.000Z - 4 weeks ago

Travere Therapeutics rises 32.5%


This Is Why Travere Therapeutics Stock (TVTX) Surged Today

2026-04-14T14:05:16.000Z - 4 weeks ago

This Is Why Travere Therapeutics Stock (TVTX) Surged Today

LGND


Travere Therapeutics Transcript: Study update

Apr 13, 2026, 6:45 PM EDT - 4 weeks ago

Travere Therapeutics Transcript: Study update


Travere Therapeutics Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:30 PM EST - 2 months ago

Travere Therapeutics Earnings Call Transcript: Q4 2025


Travere Therapeutics Provides Corporate Update and 2026 Outlook

Jan 12, 2026, 5:00 PM EST - 4 months ago

Travere Therapeutics Provides Corporate Update and 2026 Outlook


Travere Therapeutics Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 6 months ago

Travere Therapeutics Earnings Call Transcript: Q3 2025


Travere Therapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 9 months ago

Travere Therapeutics Earnings Call Transcript: Q2 2025


Holdyn_Baggins
Holdyn_Baggins May. 12 at 6:16 PM
$TVTX come on bulls. Get off the damn short bus and join us on the short train.
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 11 at 5:30 PM
$TVTX trading this thing is like playing with a balloon. It just kind of floats around. Kind of fun. I flipped it long last time so don’t say I never did anything for you bulls.
0 · Reply
gookvook
gookvook May. 10 at 6:25 PM
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 7 at 4:08 PM
$TVTX so good… mmm mmm
0 · Reply
DeadInvestor
DeadInvestor May. 7 at 3:55 PM
$TVTX My math suggests $3.9 billion peak sales. IgAN at 990 PSFs per quarter is 1.5% of 70,000 population. Thats 6% per year. Assume this peaks at 1/3rd of population, who remain on Filspari in perpetuity, assuming a $90K net revenue (payer discount and royalties owed), that’s $2.1 billion in annual sales. Assuming FSGS can also get to 1/3rd of 30,000 population, at a $180K net revenue, that’s another $1.8 billion. $3.9 billion combined, without expanding TAM population (which TVTX intends to do). Fair valuation conservatively at 2x sales, that’s $7.8 billion market cap, or $81 / share.
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 7 at 3:53 PM
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 7 at 3:51 PM
$TVTX FREE MONEY!!!
0 · Reply
DeadInvestor
DeadInvestor May. 7 at 3:17 PM
$TVTX @Night_Owl_Biotech Will you update and share your biotech valuation tables, now with FSGS approval and expectation of $3.1 billion peak Filspari sales? Curious how under valued TVTX is now, as compared to similar biotechs.
3 · Reply
DeadInvestor
DeadInvestor May. 7 at 3:13 PM
$TVTX I believe $NVS is lead acquirer now, after failed endpoint not met on IgAN trial. They will still submit to FDA, but unlikely to approve. Therefore acquire TVTX at $75 / share.
0 · Reply
DeadInvestor
DeadInvestor May. 7 at 3:10 PM
$TVTX Convertible notes oversubscribed ($475M vs $400M offering) at a conversion price of $65 / share. This is constructed well, in that it will result in a substantial unwinding of the 15% of float short positions (Institutional holdings are currently 110% of shares outstanding). Very bullish setup. If it can push through the $55 resistance, smooth sailing to $70+ and eventual acquisition likely.
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 7 at 2:22 PM
0 · Reply
AlertsAndNews
AlertsAndNews May. 7 at 2:41 AM
$TVTX Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes "Today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes"). The sale of the Notes is expected to close on May 11, 2026, subject to customary closing conditions. The aggregate principal amount of the offering was increased from the previously announced offering size of $400.0 million."
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 6 at 9:43 PM
$TVTX retail getting dumped on by smarter money at the top of a rally. It’s called distribution. Google it.
0 · Reply
DeadInvestor
DeadInvestor May. 6 at 3:17 PM
$TVTX These analysts made changes to their price targets on Travere Therapeutics following earnings announcement. • HC Wainwright & Co. analyst Joseph Pantginis maintained the stock with a Buy and raised the price target from $47 to $57. • Wedbush analyst Laura Chico maintained the stock with an Outperform rating and raised the price target from $53 to $55. • Citigroup analyst Yigal Nochomovitz maintained Travere Therapeutics with a Buy and raised the price target from $53 to $59. • TD Cowen analyst Tyler Van Buren maintained the stock with a Buy and raised the price target from $45 to $60.
0 · Reply
TalkMarkets
TalkMarkets May. 6 at 2:00 PM
Travere Therapeutics Inc: Chart Analysis $TVTX https://talkmarkets.com/article/travere-therapeutics-inc-chart-analysis-1778076012
0 · Reply
DARKP00L
DARKP00L May. 6 at 1:33 PM
$TVTX 09:29 on May. 06 2026 Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $50 #tradeideas
0 · Reply
aztecs99
aztecs99 May. 6 at 1:03 PM
the brand new chart of the week is out for 5/6, and it is Travere Therapeutics! $TVTX Watch it here! https://explosiveoptions.net/options-trading-charts/travere-therapeutics-inc/
0 · Reply
AXLFI_HQ
AXLFI_HQ May. 6 at 1:00 AM
$TVTX Healthcare providers and medical device manufacturers report strong Q1 2026 earnings driven by product approvals, expanded commercial investments, and accelerating procedure volumes with margin expansion from operational efficiency. Learn more: https://axlfi.com/themes/220
0 · Reply
Holdyn_Baggins
Holdyn_Baggins May. 5 at 8:28 PM
0 · Reply
Merlintrader
Merlintrader May. 5 at 7:56 PM
0 · Reply
Buckeyeboy722
Buckeyeboy722 May. 5 at 7:34 PM
$TVTX the feed is so much better when you block the trolls that have nothing to offer in the way of insight or intelligence.
0 · Reply
eli72
eli72 May. 5 at 5:59 PM
$TVTX fair value 88.4$ https://finance.yahoo.com/markets/stocks/articles/3-stocks-estimated-discounts-44-113813981.html
0 · Reply